UA82435C2 - Конденсированные гетероцикличиские соединения и их применение как метаботропных антагонистов рецепторов глутамата, фармацевтическая композиция на их основе - Google Patents

Конденсированные гетероцикличиские соединения и их применение как метаботропных антагонистов рецепторов глутамата, фармацевтическая композиция на их основе Download PDF

Info

Publication number: UA82435C2
Authority: UA; Ukraine
Prior art keywords: compound according; tetrahydro; valkyl; group; chlorophenyl
Prior art date: 2004-02-18

Application number

UAA200608820A

Other languages

English (en)

Ukrainian (uk)

Inventor

Мартин Йохансон

Дейвид Венсбо

Александер Минидис

Карин Стааф

Луиз Эдвардс

Томислав Стефанак

Абдельмалик Слесси

Доналд Маклеод

Тао Синь

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-02-18

Filing date

2005-02-17

Publication date

2008-04-10

2005-02-17 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2008-04-10 Publication of UA82435C2 publication Critical patent/UA82435C2/ru

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Diabetes (AREA)
Psychiatry (AREA)
Pulmonology (AREA)
Physical Education & Sports Medicine (AREA)
Obesity (AREA)
Rheumatology (AREA)
Ophthalmology & Optometry (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Reproductive Health (AREA)
Orthopedic Medicine & Surgery (AREA)
Psychology (AREA)
Endocrinology (AREA)
Epidemiology (AREA)
Gynecology & Obstetrics (AREA)
Hospice & Palliative Care (AREA)
Child & Adolescent Psychology (AREA)
Heart & Thoracic Surgery (AREA)
Immunology (AREA)
Dermatology (AREA)
Emergency Medicine (AREA)

UAA200608820A 2004-02-18 2005-02-17 Конденсированные гетероцикличиские соединения и их применение как метаботропных антагонистов рецепторов глутамата, фармацевтическая композиция на их основе UA82435C2 (ru)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US54528804P	2004-02-18	2004-02-18
US54558004P	2004-02-19	2004-02-19
PCT/US2005/005218 WO2005080397A2 (en)	2004-02-18	2005-02-17	Fused hetrocyclic compounds and their use as metabotropic receptor antagonists for the treatment of gastrointestinal disorders

Publications (1)

Publication Number	Publication Date
UA82435C2 true UA82435C2 (ru)	2008-04-10

Family

ID=34886171

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UAA200608820A UA82435C2 (ru)	2004-02-18	2005-02-17	Конденсированные гетероцикличиские соединения и их применение как метаботропных антагонистов рецепторов глутамата, фармацевтическая композиция на их основе

Country Status (21)

Country	Link
US (1)	US20070185095A1 (ru)
EP (1)	EP1716152B1 (ru)
JP (1)	JP2007523183A (ru)
KR (1)	KR20070026380A (ru)
CN (1)	CN1934112A (ru)
AT (1)	ATE402935T1 (ru)
BR (1)	BRPI0507495A (ru)
CA (1)	CA2556320A1 (ru)
DE (1)	DE602005008558D1 (ru)
DK (1)	DK1716152T3 (ru)
ES (1)	ES2309718T3 (ru)
HR (1)	HRP20080480T3 (ru)
IL (1)	IL177291A0 (ru)
MY (1)	MY152888A (ru)
PL (1)	PL1716152T3 (ru)
PT (1)	PT1716152E (ru)
RU (1)	RU2006129324A (ru)
SI (1)	SI1716152T1 (ru)
UA (1)	UA82435C2 (ru)
WO (1)	WO2005080397A2 (ru)
ZA (1)	ZA200606508B (ru)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP4637578B2 (ja)	2002-08-09	2011-02-23	アストラゼネカアクチボラグ	代謝調節型グルタミン酸受容体−５の調節因子としての１，２，４−オキサジアゾール類
US7807706B2 (en)	2005-08-12	2010-10-05	Astrazeneca Ab	Metabotropic glutamate-receptor-potentiating isoindolones
AR058807A1 (es)	2005-09-29	2008-02-27	Astrazeneca Ab	5-(fenilisoxazoletoxi)-triazol-3-il piridinas sustituidas, para el tratamiento de trastornos mediados por el receptor mglur5
TW200811179A (en) *	2006-05-05	2008-03-01	Astrazeneca Ab	mGluR5 modulators VI
TW200811157A (en)	2006-05-05	2008-03-01	Astrazeneca Ab	mGluR5 modulators I
TW200808800A (en) *	2006-05-05	2008-02-16	Astrazeneca Ab	MGluR5 modulators V
EP2119719A1 (en) *	2006-12-26	2009-11-18	Daiichi Sankyo Company, Limited	Thiazepine derivative
TW200911255A (en)	2007-06-07	2009-03-16	Astrazeneca Ab	Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators-841
TWI417100B (zh) *	2007-06-07	2013-12-01	Astrazeneca Ab	二唑衍生物及其作為代謝型麩胺酸受體增效劑-８４２之用途
TW200924774A (en) *	2007-10-26	2009-06-16	Astrazeneca Ab	Fused pyrrolidine 1,2,4-triazole derivatives as modulators of mGluR5
WO2009054786A1 (en) *	2007-10-26	2009-04-30	Astrazeneca Ab	1,2,4-triazole aryl n-oxides derivatives as modulators of mglur5
WO2009054792A1 (en) *	2007-10-26	2009-04-30	Astrazeneca Ab	Aminopyridine derivatives as modulators of mglur5
TW200922586A (en) *	2007-10-26	2009-06-01	Astrazeneca Ab	Thiophene 1,2,4-triazole derivatives as modulators of mGluR5
WO2009054789A1 (en) *	2007-10-26	2009-04-30	Astrazeneca Ab	1,2,3-triazole pyrrolidine derivatives as modulators of mglur5
SA109300358B1 (ar)	2008-06-06	2012-11-03	استرازينيكا ايه بي	مقويات مستقبل جلوتامات ذي انتحاء أيضي من أيزو إندولون
US8349852B2 (en)	2009-01-13	2013-01-08	Novartis Ag	Quinazolinone derivatives useful as vanilloid antagonists
ES2472446T3 (es)	2009-11-30	2014-07-01	Novartis Ag	Derivados de imidazol como inhibidores de aldosterona sintasa
EP2519521B1 (en)	2009-12-29	2013-11-20	Eli Lilly and Company	Tetrahydrotriazolopyridine compounds as selective mglu5 receptor potentiators useful for the treatment of schizophrenia
US20120295942A1 (en)	2010-02-01	2012-11-22	Nicholas James Devereux	Pyrazolo[5,1b]oxazole Derivatives as CRF-1 Receptor Antagonists
WO2011092293A2 (en)	2010-02-01	2011-08-04	Novartis Ag	Cyclohexyl amide derivatives as crf receptor antagonists
CN102753527B (zh)	2010-02-02	2014-12-24	诺华股份有限公司	用作crf受体拮抗剂的环己基酰胺衍生物
US10065960B2 (en)	2010-04-02	2018-09-04	Ogeda Sa	NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders
PL2552920T3 (pl)	2010-04-02	2017-08-31	Ogeda Sa	Nowe wybiórcze związki antagonistów receptora NK-3, farmaceutyczne kompozycje i sposoby do zastosowania w zaburzeniach pośredniczonych przez receptory NK-3
AU2011245737A1 (en) *	2010-04-30	2012-12-20	Astrazeneca Ab	Polymorphs of a metabotropic glutamate receptor positive allosteric modulator
CA2849751C (en)	2011-10-03	2019-06-11	Euroscreen Sa	Chiral n-acyl-5,6,7,(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective nk-3 receptor antagonists, pharmaceutical composition, methods for use in nk-3 receptormediated disorders and chiral synthesis thereof
US10183948B2 (en)	2013-03-29	2019-01-22	Ogeda Sa	N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists
ES2711143T3 (es)	2013-03-29	2019-04-30	Ogeda Sa	N-acil-(3-sustituido)-5,6,7,8-tetrahidro-[1,2,4]triazolo[4,3-a]pirazinas como antagonistas selectivos del receptor de NK-3, composición farmacéutica, métodos para su uso en los trastornos mediados por el receptor de NK-3
JP6275242B2 (ja)	2013-03-29	2018-02-07	オゲダエス．エー．	選択的ＮＫ−３受容体拮抗薬としての新規なＮ−アシル−（３位置換）−（８−メチル）−５，６−ジヒドロ−［１，２，４］トリアゾロ［４，３−ａ］ピラジン、その医薬組成物、ＮＫ−３受容体媒介性障害で使用する方法
LT2948455T (lt)	2013-03-29	2017-11-27	Ogeda S.A.	N-acil-(3-pakeisto)-(8-pakeisto)-5,6-dihidro- [1,2,4]triazol[4,3-a]pirazinai, kaip selektyvūs nk-3 receptorių antagonistai, farmacinė kompozicija, būdai, skirti naudoti nk-3 receptoriaus sąlygotų sutrikimų gydymui
GB201312800D0 (en)	2013-07-17	2013-08-28	Heptares Therapeutics Ltd	mGlu5 modulators
TR201902080T4 (tr)	2014-09-25	2019-03-21	Ogeda Sa	N-asil-(3-sübstitüe)-(8-sübstitüe)-5,6-dihidro-[1,2,4]triazolo[4,3-a]pirazinlerinin yeni kiral sentezleri.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR100875222B1 (ko) *	1999-08-19	2008-12-19	아스트라제네카 아베	헤테로폴리사이클릭 화합물 및 간접 글루타메이트 수용체길항제로서의 그들의 용도
JP2006502134A (ja) *	2002-08-09	2006-01-19	アストラゼネカアクチボラグ	代謝調節型グルタミン酸受容体において活性を有する化合物

2005
- 2005-02-17 JP JP2006554237A patent/JP2007523183A/ja not_active Withdrawn
- 2005-02-17 WO PCT/US2005/005218 patent/WO2005080397A2/en not_active Ceased
- 2005-02-17 DE DE602005008558T patent/DE602005008558D1/de not_active Expired - Fee Related
- 2005-02-17 EP EP05713794A patent/EP1716152B1/en not_active Expired - Lifetime
- 2005-02-17 DK DK05713794T patent/DK1716152T3/da active
- 2005-02-17 PT PT05713794T patent/PT1716152E/pt unknown
- 2005-02-17 BR BRPI0507495-9A patent/BRPI0507495A/pt not_active IP Right Cessation
- 2005-02-17 CN CN200580008454.2A patent/CN1934112A/zh active Pending
- 2005-02-17 US US10/588,699 patent/US20070185095A1/en not_active Abandoned
- 2005-02-17 AT AT05713794T patent/ATE402935T1/de not_active IP Right Cessation
- 2005-02-17 HR HR20080480T patent/HRP20080480T3/xx unknown
- 2005-02-17 RU RU2006129324/04A patent/RU2006129324A/ru not_active Application Discontinuation
- 2005-02-17 UA UAA200608820A patent/UA82435C2/ru unknown
- 2005-02-17 ES ES05713794T patent/ES2309718T3/es not_active Expired - Lifetime
- 2005-02-17 CA CA002556320A patent/CA2556320A1/en not_active Abandoned
- 2005-02-17 SI SI200530394T patent/SI1716152T1/sl unknown
- 2005-02-17 PL PL05713794T patent/PL1716152T3/pl unknown
- 2005-02-17 MY MYPI20050602 patent/MY152888A/en unknown
- 2005-02-17 KR KR1020067015826A patent/KR20070026380A/ko not_active Withdrawn
2006
- 2006-08-03 IL IL177291A patent/IL177291A0/en unknown
- 2006-08-04 ZA ZA200606508A patent/ZA200606508B/en unknown

Also Published As

Publication number	Publication date
ATE402935T1 (de)	2008-08-15
MY152888A (en)	2014-11-28
SI1716152T1 (sl)	2008-12-31
HK1098460A1 (en)	2007-07-20
WO2005080397A3 (en)	2005-12-22
CN1934112A (zh)	2007-03-21
WO2005080397A2 (en)	2005-09-01
PT1716152E (pt)	2008-10-02
EP1716152A2 (en)	2006-11-02
KR20070026380A (ko)	2007-03-08
DK1716152T3 (da)	2008-11-03
PL1716152T3 (pl)	2009-01-30
DE602005008558D1 (de)	2008-09-11
US20070185095A1 (en)	2007-08-09
IL177291A0 (en)	2006-12-10
CA2556320A1 (en)	2005-09-01
EP1716152B1 (en)	2008-07-30
RU2006129324A (ru)	2008-04-10
ZA200606508B (en)	2007-11-28
JP2007523183A (ja)	2007-08-16
ES2309718T3 (es)	2008-12-16
HRP20080480T3 (hr)	2008-11-30
WO2005080397A8 (en)	2006-06-22
BRPI0507495A (pt)	2007-07-10

Publication	Publication Date	Title
UA82435C2 (ru)	2008-04-10	Конденсированные гетероцикличиские соединения и их применение как метаботропных антагонистов рецепторов глутамата, фармацевтическая композиция на их основе
JP5084269B2 (ja)	2012-11-28	テトラゾール化合物及び代謝共役型グルタミン酸受容体アンタゴニストとしてのそれらの使用
US11905297B2 (en)	2024-02-20	OX2R compounds
US20060019997A1 (en)	2006-01-26	Triazole compounds and their use as metabotropic glutamate receptor antagonists
US11168079B2 (en)	2021-11-09	Alkene compounds as farnesoid x receptor modulators
AU2007303889B2 (en)	2011-02-24	mGluR5 modulators
EP4117784B1 (en)	2024-08-28	Gpr52 modulator compounds
AU2006295645A1 (en)	2007-04-05	2-heteroaryl-substituted indole derivative
AU2018246355B2 (en)	2021-12-09	2-oxo-thiazole derivatives as A2A inhibitors and compounds for use in the treatment of cancers
CA2555272A1 (en)	2005-09-01	Polyheterocyclic compounds and their use as metabotropic glutamate receptor antagonists
US11370785B2 (en)	2022-06-28	Multicyclic compounds as farnesoid X receptor modulators
US20250115587A1 (en)	2025-04-10	Pyrazole derivatives as h4 antagonist compounds
US9051295B2 (en)	2015-06-09	1-substituted indazole derivative
CA2507186A1 (en)	2004-06-17	Anilinopyrazole derivatives useful for the treatment of diabetes
US20230250095A1 (en)	2023-08-10	Benzimidazole derivatives, preparation method therefor and medical use thereof
US7576077B2 (en)	2009-08-18	Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists
US20170340621A1 (en)	2017-11-30	Sulfonyl piperidine derivatives and their use for treating prokineticin mediated gastrointestinal disorders
US20230348516A1 (en)	2023-11-02	Ykl-40 inhibitors and their therapeutic applications
CA3180853A1 (en)	2021-10-28	H4 antagonist compounds
BR112020004332A2 (pt)	2020-09-08	derivados de 1-(4-isoxazol-5-il)-1h-pirazol-1-il)-2-metilpropan-2-ol e compostos relacionados como inibidores de il-17 e ifn-gama para o tratamento de doenças autoimunes e inflamação crônica
HK1098460B (en)	2009-02-13	Fused hetrocyclic compounds and their use as metabotropic receptor antagonists for the treatment of gastrointestinal disorders